1. The brain microvasculature is a primary mediator of interferon-α neurotoxicity in human cerebral interferonopathies.
- Author
-
Viengkhou B, Hayashida E, McGlasson S, Emelianova K, Forbes D, Wiseman S, Wardlaw J, Verdillo R, Irani SR, Duffy D, Piehl F, Loo L, Pagenstecher A, Neely GG, Crow YJ, Campbell IL, Hunt DPJ, and Hofer MJ
- Subjects
- Animals, Humans, Mice, Autoimmune Diseases of the Nervous System immunology, Endothelial Cells metabolism, Mice, Knockout, Male, Female, Signal Transduction, Mice, Inbred C57BL, Astrocytes metabolism, Disease Models, Animal, Interferon-alpha metabolism, Brain metabolism, Brain pathology, Receptor, Interferon alpha-beta metabolism, Receptor, Interferon alpha-beta genetics, Microvessels pathology, Nervous System Malformations genetics
- Abstract
Aicardi-Goutières syndrome (AGS) is an autoinflammatory disease characterized by aberrant interferon (IFN)-α production. The major cause of morbidity in AGS is brain disease, yet the primary source and target of neurotoxic IFN-α remain unclear. Here, we demonstrated that the brain was the primary source of neurotoxic IFN-α in AGS and confirmed the neurotoxicity of intracerebral IFN-α using astrocyte-driven Ifna1 misexpression in mice. Using single-cell RNA sequencing, we demonstrated that intracerebral IFN-α-activated receptor (IFNAR) signaling within cerebral endothelial cells caused a distinctive cerebral small vessel disease similar to that observed in individuals with AGS. Magnetic resonance imaging (MRI) and single-molecule ELISA revealed that central and not peripheral IFN-α was the primary determinant of microvascular disease in humans. Ablation of endothelial Ifnar1 in mice rescued microvascular disease, stopped the development of diffuse brain disease, and prolonged lifespan. These results identify the cerebral microvasculature as a primary mediator of IFN-α neurotoxicity in AGS, representing an accessible target for therapeutic intervention., Competing Interests: Declaration of interests I.L.C. and M.J.H. received funding from Ionis Pharmaceuticals for experiments in an unrelated study using the GIFN mice., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF